Inflammatory cerebral amyloid angiopathy and amyloid-modifying therapies: Variations on the Same ARIA?

Annals of Neurology

Volumn 73, Issue 4, 2013, Pages 439-441

  Werring, David J ^a   Sperling, Reisa ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BAPINEUZUMAB;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOID RELATED IMAGING ABNORMALITY; BRAIN HEMORRHAGE; HUMAN; IMMUNOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; VASCULAR AMYLOIDOSIS;

AMYLOID BETA-PEPTIDES; AUTOANTIBODIES; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HUMANS; INFLAMMATION; MALE;

EID: 84878389295     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23891     Document Type: Review

References (16)

1. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379.
2. Wilcock DM, Colton CA,. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 2009; 8: 50-64.
3. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010; 24: 198-203.
4. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73: 2061-2070.
5. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7: 367-385.
6. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11: 241-249.
7. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69: 198-207.
8. Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1430-1440.
9. Carlson C, Estergard W, Oh J, et al. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 2011; 7: 396-401.
10. Cordonnier C, van der Flier WM,. Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 2011; 134 (pt 2): 335-344.
11. Charidimou A, Gang Q, Werring DJ,. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012; 83: 124-137.
12. Charidimou A, Peeters A, Fox Z, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke 2012; 43: 2324-2330.
13. Eng JA, Frosch MP, Choi K, et al. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004; 55: 250-256.
14. Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128 (pt 3): 500-515.
15. DiFrancesco JC, Brioschi M, Brighina L, et al. Anti-Abeta autoantibodies in the CSF of a patient with CAA-related inflammation: a case report. Neurology 2011; 76: 842-844.
16. Piazza F, Greenberg SM, Savoiardo M, et al. Anti-Aβ autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 2013; 73: 450-459.